Literature DB >> 11283541

p16(INK4a) alterations in chronic pancreatitis-indicator for high-risk lesions for pancreatic cancer.

B Gerdes1, A Ramaswamy, M Kersting, M Ernst, S Lang, M Schuermann, A Wild, D K Bartsch.   

Abstract

BACKGROUND: p16(INK4a) alterations are considered to be an early event in pancreatic tumorigenesis and have been described in duct lesions adjacent to pancreatic cancers. This study evaluates whether duct lesions in chronic pancreatitis tissues of patients without pancreatic cancer also harbor genetic alterations in the p16(INK4a) tumor-suppressor gene, and thus represent high-risk precursors for pancreatic cancer.
METHODS: Tissues were obtained from 20 pancreatic specimens taken from patients operated on for histologically verified chronic pancreatitis. Pancreatic intraductal neoplasias (PanIN) were identified in hematoxylin-and-eosin-stained slides. p16 protein expression was investigated immunohistochemically in all specimens. DNA from PanIN and non-PanIN tissue was analyzed genetically for p16(INK4a) mutations by single-strand conformation variation analysis and direct sequencing of the encoding region. Additionally, p16(INK4a) promoter methylation was analyzed by a methylation specific polymerase test.
RESULTS: PanIN-1a lesions were identified in 10 of the 20 chronic pancreatitis specimens. Four of these 10 PanIN specimens (40%), but none of the 20 non-PanIN tissues, revealed a loss of p16 expression in immunohistochemistry. The mutational analysis of the p16(INK4a) gene showed 1 known polymorphism (c.442G > A; A148T) but no mutations. Two of the 10 specimens with PanIN revealed an inactivating hypermethylation of the p16(INK4a) promoter.
CONCLUSIONS: This study shows for the first time that p16(INK4a) alterations can be observed in a considerable number of PanIN1 in chronic pancreatitis tissues not associated with pancreatic cancer. Therefore, p16(INK4a) alterations, especially promoter methylation, might indicate high-risk precursors in chronic pancreatitis that might progress to cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11283541     DOI: 10.1067/msy.2001.112071

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  9 in total

Review 1.  Advances in biomarker research for pancreatic cancer.

Authors:  Kruttika Bhat; Fengfei Wang; Qingyong Ma; Qinyu Li; Sanku Mallik; Tze-Chen Hsieh; Erxi Wu
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

2.  Clinical significance of K-ras and c-erbB-2 mutations in pancreatic adenocarcinoma and chronic pancreatitis.

Authors:  Renata Talar-Wojnarowska; Anita Gasiorowska; Beata Smolarz; Hanna Romanowicz-Makowska; Janusz Strzelczyk; Adam Janiak; Andrzej Kulig; Ewa Malecka-Panas
Journal:  Int J Gastrointest Cancer       Date:  2005

3.  Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma.

Authors:  Noriyoshi Fukushima; Norihiro Sato; Takashi Ueki; Christophe Rosty; Kimberly M Walter; Robb E Wilentz; Charles J Yeo; Ralph H Hruban; Michael Goggins
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

Review 4.  Phenotype and genotype of pancreatic cancer cell lines.

Authors:  Emily L Deer; Jessica González-Hernández; Jill D Coursen; Jill E Shea; Josephat Ngatia; Courtney L Scaife; Matthew A Firpo; Sean J Mulvihill
Journal:  Pancreas       Date:  2010-05       Impact factor: 3.327

Review 5.  Values of mutations of K-ras oncogene at codon 12 in detection of pancreatic cancer: 15-year experience.

Authors:  De-Qing Mu; You-Shu Peng; Qiao-Jian Xu
Journal:  World J Gastroenterol       Date:  2004-02-15       Impact factor: 5.742

Review 6.  An overview of genetic mutations and epigenetic signatures in the course of pancreatic cancer progression.

Authors:  Aamir Ali Khan; Xinhui Liu; Xinlong Yan; Muhammad Tahir; Sakhawat Ali; Hua Huang
Journal:  Cancer Metastasis Rev       Date:  2021-01-10       Impact factor: 9.264

7.  Alterations of tumor suppressor gene p16INK4a in pancreatic ductal carcinoma.

Authors:  Jyotika Attri; Radhika Srinivasan; Siddhartha Majumdar; Bishan Dass Radotra; Jaidev Wig
Journal:  BMC Gastroenterol       Date:  2005-06-28       Impact factor: 3.067

Review 8.  Clinicopathological Significance of CDKN2A Promoter Hypermethylation Frequency with Pancreatic Cancer.

Authors:  Bo Tang; Yang Li; Guangying Qi; Shengguang Yuan; Zhenran Wang; Shuiping Yu; Bo Li; Songqing He
Journal:  Sci Rep       Date:  2015-09-04       Impact factor: 4.379

Review 9.  Deciphering DNA methylation signatures of pancreatic cancer and pancreatitis.

Authors:  Francesco Natale; Maria Vivo; Geppino Falco; Tiziana Angrisano
Journal:  Clin Epigenetics       Date:  2019-09-06       Impact factor: 6.551

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.